Aligned Genetics Past Earnings Performance
Past criteria checks 4/6
Aligned Genetics has been growing earnings at an average annual rate of 47%, while the Life Sciences industry saw earnings growing at 21.5% annually. Revenues have been growing at an average rate of 19.3% per year. Aligned Genetics's return on equity is 10.3%, and it has net margins of 21.3%.
Key information
47.0%
Earnings growth rate
43.5%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 19.3% |
| Return on equity | 10.3% |
| Net Margin | 21.3% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Aligned Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 15,215 | 3,236 | 5,125 | 1,684 |
| 30 Sep 23 | 14,209 | 1,775 | 4,862 | 1,427 |
| 30 Jun 23 | 14,072 | 2,188 | 4,796 | 1,352 |
| 31 Mar 23 | 13,764 | 2,113 | 4,539 | 1,327 |
| 31 Dec 22 | 13,753 | 2,333 | 4,275 | 1,079 |
| 30 Sep 22 | 13,889 | 5,346 | 4,444 | 986 |
| 30 Jun 22 | 12,849 | 4,177 | 4,219 | 996 |
| 31 Mar 22 | 12,942 | 4,611 | 4,037 | 877 |
| 31 Dec 21 | 11,762 | 5,542 | 3,794 | 944 |
| 30 Sep 21 | 10,346 | 3,968 | 3,378 | 949 |
| 30 Jun 21 | 10,059 | 3,337 | 3,331 | 861 |
| 31 Mar 21 | 8,322 | 1,855 | 3,356 | 924 |
| 31 Dec 20 | 7,957 | 468 | 3,466 | 816 |
| 30 Sep 20 | 7,484 | -109 | 3,501 | 825 |
| 30 Jun 20 | 7,359 | 102 | 3,931 | 644 |
| 31 Mar 20 | 7,738 | 375 | 3,691 | 820 |
| 31 Dec 19 | 7,794 | 117 | 3,629 | 885 |
| 30 Sep 19 | 7,486 | -277 | 3,653 | 1,026 |
| 30 Jun 19 | 6,799 | -864 | 3,427 | 1,252 |
| 31 Mar 19 | 6,425 | -1,014 | 3,762 | 1,083 |
| 31 Dec 18 | 5,675 | -1,588 | 3,883 | 1,156 |
| 30 Sep 18 | 5,385 | -2,098 | 4,049 | 1,034 |
| 30 Jun 18 | 5,600 | -1,801 | 4,052 | 1,017 |
| 31 Mar 18 | 5,630 | -1,881 | 3,959 | 1,208 |
| 31 Dec 17 | 5,636 | -1,754 | 4,009 | 940 |
| 30 Sep 17 | 5,487 | -1,202 | 3,830 | 801 |
| 30 Jun 17 | 5,085 | -1,689 | 3,866 | 593 |
| 31 Mar 17 | 4,806 | -1,526 | 3,626 | 465 |
| 31 Dec 16 | 4,712 | -1,556 | 3,392 | 578 |
| 30 Sep 16 | 4,407 | -1,386 | 2,992 | 600 |
| 30 Jun 16 | 4,249 | -833 | 2,524 | 715 |
| 31 Mar 16 | 4,150 | -740 | 2,588 | 612 |
| 31 Dec 15 | 4,096 | -261 | 2,341 | 587 |
| 31 Dec 14 | 2,329 | -811 | 1,334 | 552 |
Quality Earnings: A238120 has high quality earnings.
Growing Profit Margin: A238120's current net profit margins (21.3%) are higher than last year (17%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A238120 has become profitable over the past 5 years, growing earnings by 47% per year.
Accelerating Growth: A238120's earnings growth over the past year (38.7%) is below its 5-year average (47% per year).
Earnings vs Industry: A238120 earnings growth over the past year (38.7%) exceeded the Life Sciences industry 8.1%.
Return on Equity
High ROE: A238120's Return on Equity (10.3%) is considered low.